Xcout Intel
EGenesis
eGenesis, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing advanced genome-editing solutions. The company utilizes its proprietary platform to work on xenotransplantation and address organ shortages for human patients.
Subscribe to see EGenesis’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
EGenesis at a glance
EGenesis is a therapeutics company headquartered in United States. Its most recent funding round, Series D, raised $190M in September 2024. Xcout tracks 15 named people at EGenesis, including Mike Curtis (President and CEO). Xcout recorded 22 job postings from EGenesis in the last 90 days.
EGenesis leadership
- Mike CurtisPresident and CEO
- Mike Curtis, Ph.D.President & Chief Executive Officer
- Glenn VraniakChief Financial Officer
- Jay Barth, M.D.Chief Medical Officer
- Jennifer BergheiserChief Commercial Officer
- Susan Low, Ph.D.SVP, Development
9 more named people on record for EGenesis, with roles, board committees and tenure — see the full roster →
EGenesis funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $190M | 12 named | |
| SEC Form D filing | $25.4M | — | |
| SEC Form D filing | $125M | — | |
| SEC Form D filing | $100M | — | |
| SEC Form D filing | $12.6M | — | |
| SEC Form D filing | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at EGenesis
Xcout recorded 22 job postings from EGenesis in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see EGenesis's hiring signals →
Investors
Tech stack
EGenesis competitors
A few of EGenesis's closest competitors — see the full list of competitors and alternatives →
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
EdiGene is a clinical-stage biotechnology company founded in 2015 that focuses on translating gene-editing technologies into therapeutic products. Headquartered in Beijing, China, the company also operates research and office facilities in locations such as Shanghai, Guangzhou, and the United States.
KOMO Biosciences is a biotechnology research company headquartered in Cambridge, Massachusetts. The company specializes in next-generation precision genome engineering driven by highly efficient, evolved integrases.
Colossal Biosciences is a biotechnology and genetic science company headquartered in Dallas, Texas, specializing in de-extinction initiatives and advanced genomics research.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Get EGenesis's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on EGenesis in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access